Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182.
ArticleÂ
CASÂ
PubMedÂ
Google ScholarÂ
Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998, 90: 1361-1370. 10.1093/jnci/90.18.1361.
ArticleÂ
CASÂ
PubMedÂ
Google ScholarÂ
Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, Wolmark N: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst. 2000, 92: 1991-1998. 10.1093/jnci/92.24.1991.
ArticleÂ
CASÂ
PubMedÂ
Google ScholarÂ
Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrin-cione CT, Budman DR, Wood WC, Barcos M: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994, 330: 1260-1266. 10.1056/NEJM199405053301802.
ArticleÂ
CASÂ
PubMedÂ
Google ScholarÂ
Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998, 90: 1346-1360. 10.1093/jnci/90.18.1346.
ArticleÂ
CASÂ
PubMedÂ
Google ScholarÂ
Ravdin PM, Green S, KS Albain KS, Ingle J, Pritchard K, Shepard L, Davidson N, Hayes D, Clark G, Martino S, Osborne C, Allred D: Initial Report of the SWOG Biological Correlative Study of c-erbb-2 Expression as a Predictor of Outcome in a Trial Comparing Adjuvant CAFT with Tamoxifen (T) alone [abstract]. Proc Am Soc Clin Oncol. 1998, A374-
Google ScholarÂ
Sledge G: Is HER-2/neu a predictor of anthracycline utility? No. 2000, 75-[http://odp.od.nih.gov/consensus/cons/114/114_intro.htm]
Google ScholarÂ
Early Breast Cancer Trialists' Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998, 352: 930-942. 10.1016/S0140-6736(98)03301-7.
ArticleÂ
Google ScholarÂ
Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992, 84: 845-855. 10.1093/jnci/84.11.845.
ArticleÂ
CASÂ
PubMedÂ
Google ScholarÂ
Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993, 74: 957-967.
ArticleÂ
CASÂ
PubMedÂ
Google ScholarÂ
Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P: Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res. 1995, 1: 189-198.
CASÂ
PubMedÂ
Google ScholarÂ
Dublin EA, Miles DW, Rubens RD, Smith P, Barnes DM: p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer. Int J Cancer. 1997, 74: 605-608. 10.1002/(SICI)1097-0215(19971219)74:6<605::AID-IJC8>3.3.CO;2-9.
ArticleÂ
CASÂ
PubMedÂ
Google ScholarÂ
Veronese S, Mauri FA, Caffo O, Scaioli M, Aldovini D, Perrone G, Galligioni E, Doglioni C, Dalla Palma P, Barbareschi M: Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up. Int J Cancer. 1998, 79: 13-18. 10.1002/(SICI)1097-0215(19980220)79:1<13::AID-IJC3>3.0.CO;2-Z.
ArticleÂ
CASÂ
PubMedÂ
Google ScholarÂ
Degeorges A, de Roquancourt A, Extra JM, Espie M, Bourstyn E, de Cremoux P, Soussi T, Marty M: Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?. Breast Cancer Res Treat. 1998, 47: 47-55. 10.1023/A:1005824216444.
ArticleÂ
CASÂ
PubMedÂ
Google ScholarÂ
Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L: p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res. 2000, 6: 2751-2758.
CASÂ
PubMedÂ
Google ScholarÂ
Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ: p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol. 1998, 16: 470-479.
CASÂ
PubMedÂ
Google ScholarÂ
Mottolese M, Benevolo M, Del Monte G, Buglioni S, Papaldo P, Nistico C, Di Filippo F, Vasselli S, Vici P, Botti C: Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Cancer Res Clin Oncol. 2000, 126: 722-729.
ArticleÂ
CASÂ
PubMedÂ
Google ScholarÂ
Zhang CC, Yang JM, Bash-Babula J, White E, Murphy M, Levine AJ, Hait WN: DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Res. 1999, 59: 3663-3670.
CASÂ
PubMedÂ
Google ScholarÂ
Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med. 1996, 2: 72-79.
ArticleÂ
CASÂ
PubMedÂ
Google ScholarÂ
Sjostrom J, Blomqvist C, Heikkila P, Boguslawski KV, Raisanen-Sokolowski A, Bengtsson NO, Mjaaland I, Malmstrom P, Ostenstadt B, Bergh J, Wist E, Valvere V, Saksela E: Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res. 2000, 6: 3103-3110.
CASÂ
PubMedÂ
Google ScholarÂ
Eskes R, Antonsson B, Osen-Sand A, Montessuit S, Richter C, Sadoul R, Mazzei G, Nichols A, Martinou JC: Bax-induced cytochrome C release from mitochondria is independent of the permeability transition pore but highly dependent on Mg2+ ions. J Cell Biol. 1998, 143: 217-224. 10.1083/jcb.143.1.217.
ArticleÂ
CASÂ
PubMedÂ
PubMed CentralÂ
Google ScholarÂ
Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer. 1995, 72: 354-360.
ArticleÂ
CASÂ
PubMedÂ
PubMed CentralÂ
Google ScholarÂ
van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van de Velde CJ, van de Vijver MJ: Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer. 1996, 74: 78-85.
ArticleÂ
CASÂ
PubMedÂ
PubMed CentralÂ
Google ScholarÂ
Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R: Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol. 2000, 18: 1423-1431.
CASÂ
PubMedÂ
Google ScholarÂ